Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6684723 | 1.00 | CYP2C9 (0.50) | CYP2C9CYP2C19MAPK14ALDH1A1L3MBTL1 | |
| SCHEMBL7139747 | 0.88 | UCHL1 (0.47) | CYP2C9CYP2C19MAPK14ALDH1A1L3MBTL1 | |
| SCHEMBL7143741 | 0.88 | UCHL1 (0.47) | CYP2C9CYP2C19MAPK14ALDH1A1L3MBTL1 | |
| SCHEMBL6692481 | 0.87 | CYP2C9 (0.50) | CYP2C9CYP2C19MAPK14ALDH1A1L3MBTL1 | |
| SCHEMBL6692489 | 0.87 | CYP2C9 (0.50) | CYP2C9CYP2C19MAPK14ALDH1A1L3MBTL1 | |
| SCHEMBL6679116 | 0.84 | TACR3 (0.51) | CYP2C9CYP2C19MAPK14ALDH1A1L3MBTL1 | |
| SCHEMBL6659777 | 0.76 | HRH3 (0.57) | CYP2C9CYP2C19MAPK14ALDH1A1L3MBTL1 | |
| SCHEMBL7142421 | 0.74 | ALDH1A1 (0.46) | CYP2C9CYP2C19MAPK14ALDH1A1L3MBTL1 | |
| SCHEMBL6691355 | 0.74 | ALDH1A1 (0.46) | CYP2C9CYP2C19MAPK14ALDH1A1L3MBTL1 | |
| SCHEMBL6907072 | 0.74 | POLB (0.52) | CYP2C19L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257544-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1441728-A2 | MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY | Vertex Pharmaceuticals Incorporated (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040034019-A1 | Piperazine and piperidine derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-19 | — | — | US | disclosed |
| WO-2003037338-A2 | MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1257544-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | Vertex Pharmaceuticals Incorporated (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001058891-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034019-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | CYP2C9 4866/4885CYP2C19 4725/4885MAPK14 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.